Research has shown that using bebtelovimab to treat COVID-19 in an outpatient setting has been associated with lower odds of hospitalization or death, particularly among immunocompromised and older patients.
A retrospective cohort study compared bebtelovimab-treated patients to propensity score-adjusted and matched non-treated control groups. Participants included high-risk outpatients eligible for bebtelovimab treatment under Emergency Use Authorization with a positive SARS-CoV-2 test from March 30 to May 28, 2022. Treated patients received single-dose intravenous treatment with bebtelovimab. The primary outcome was hospitalization or death over 28 days.
Please review the full article from Oxford University Press on behalf of Infectious Diseases Society of America to see results of the study. (Tina Seery)
